This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Martin Scott
Scientific Leader and GSK Fellow at GlaxoSmithKline


Following undergraduate and postgraduate studies in infectious diseases at the University of Edinburgh and the Medical Research Council Virology Unit respectively, Martin joined GSK in 2002, first supporting and then leading numerous drug discovery programs. For the last few years, he has been working to accelerate the delivery of candidate biopharmaceutical molecules through the integration of innovative antibody discovery platforms and novel technologies, with a recent therapeutic focus on addressing major public health threats in infectious diseases (antimicrobial resistance, COVID-19), and in oncology. Martin is currently Scientific Leader and GSK Fellow in the department of Biopharm Discovery.

Agenda Sessions

  • Early Identification of Risk Factors for Failure in Preclinical and Clinical Development Campaigns